Bioinformatics

Italy

Bioinformatics

Italy
SEARCH FILTERS
Time filter
Source Type

This report deals with cytogenetics in a broader sense rather than the classical use mainly to describe the chromosome structure and identify abnormalities related to disease. In the age of molecular biology, it is also referred to as molecular cytogenetics. The scope of cytogenetics includes several technologies besides fluorescence in situ hybridization (FISH), comparative genomic hybridization (CGH), and multicolor FISH. Molecular cytogenetics includes application of nanobiotechnology, microarrays, real-time polymerase chain reaction (PCR), in vivo imaging, and single molecule detection. Bioinformatics is described briefly as it plays an important role in analyzing data from many of these technologies. FISH remains the single most important technology in cytogenetics. Several innovations are described of which the most important are single copy FISH, in vivo FISH (imaging of nucleic acids in living cells) and nanotechnology-based FISH. The unique character of peptide nucleic acid (PNA) allows these probes to hybridize to target nucleic acid molecules more rapidly and with higher affinity and specificity compared with DNA probes. PNA-FISH is more suited for rapid diagnosis of infections. RNA-FISH and locked nucleic acids (LNAs), are also described. Microarray/biochip-based technologies for cytogenetics promise to speed up detection of chromosome aberrations now examined by FISH. Other important genomic technologies are whole genome expression array and direct molecular analysis without amplification. Analysis of single-cell gene expression promises a more precise understanding of human disease pathogenesis and has important diagnostic applications. Optical Mapping can survey entire human genomes for insertions/deletions, which account for a significantly greater proportion of genetic variation between closely-related genomes as compared to single nucleotide polymorphisms (SNPs), and are a major cause of gene defects. The report includes summary profiles of 69 companies relevant to cytogenetics along with their 80 collaborations. Companies developing innovative technologies as well as those supplying equipment/services/reagents are identified. The report text is supplemented with 27 Tables and 9 figures. Selected 200 references are included in the bibliography. Key Topics Covered: Executive Summary 1. Introduction 2. Technologies used for cytogenetics 3. Fluorescent In Situ Hybridization 4. Genomic Technologies relevant to Cytogenetics 5. Molecular Imaging & Single Molecular Detection 6. Role of Nanobiotechnology in Cytogenetics 7. Biomarkers and Cytogenetics 8. Applications of Cytogenetics 9. Cancer Cytogenetics 10. Cytogenetics Markets 11. Companies 12. References For more information about this report visit http://www.researchandmarkets.com/research/vzv3hl/cytogenetics Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/global-2017-cytogenetics-technologies-markets-and-companies-report---projections-to-2026-69-companies-with-80-collaborations---research-and-markets-300455435.html


"Cost was a limiting factor for panels with a large number of amplicons. For researchers that need to change their gene content frequently, the lower price for oligos is really great," said Pan Zhang, Ph.D., M.D., director, Sequencing and Microarray Center at Coriell Institute for Medical Research. Adam Ameur, Ph.D., Bioinformatics Scientist, National Genomics Infrastructure, SciLifeLab at Uppsala University, added: "The majority of the projects we provide service for have only a few samples, so it is good to have a small pack size. Previously, we have been limited because of the cost, so this may open up other studies in which we look at larger genes with fewer samples." Ion AmpliSeq On-Demand Panels are custom designed by customers on the Ion AmpliSeq Designer tool (www.ampliseq.com) by selecting from a growing repository of highly optimized gene targets that are relevant in germline disorder research. The tool's disease-gene database, which allows gene selection based on disease research area, has been informed by public repositories, such as the Medical Subject Headings (MeSH) database, and includes primer sets based on 1,000's of proven designs that are also wet lab verified to guarantee performance. Panels are then ordered instantaneously in practical pack sizes that fit experiment needs and lower upfront costs. "Targeted sequencing using customer-designed custom panels has proven to be a popular method for driving translational research, but for uncommon, complex diseases such as germline disorders, most labs do not have the number of samples to justify the significant investment of time and money," said Joydeep Goswami, president of Clinical Next-Generation Sequencing and Oncology at Thermo Fisher Scientific. "By simplifying the way users can customize their content and pack delivery size, clinical researchers can focus on targets of interest that will drive greater discovery without the high upfront cost and risk of waste." Thermo Fisher will provide demonstrations of the new Ion AmpliSeq Designer Software for delegates who request them at ESHG 2017.  The company is also hosting a workshop featuring talks from early access users of Ion AmpliSeq On-Demand Panels and other new technology from Thermo Fisher. The complementary workshop, titled New Products to Enable Discovery of De Novo and Germline Mutations, will take place Sunday, May 28 at 11:15 am CET in the Ballerup Room at the Bella Center Copenhagen (BCC). Workshop presenters include: Additional Ion Torrent NGS products to be highlighted at ESHG 2017 include: For more information on the Ion AmpliSeq On-Demand Panels, stop by Thermo Fisher's booth (#438) or visit www.thermofisher.com/ampliseqondemand.html. For more information on the workshop at ESHG, visit www.thermofisher.com/eshg17. Ion AmpliSeq On-Demand Panels, Ion ReproSeq PGS Kits and Ion 510 Chip are For Research Use Only; not for use in diagnostic procedures. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with revenues of $18 billion and more than 55,000 employees globally. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity. Through our premier brands – Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services – we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive support. For more information, please visit www.thermofisher.com. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/new-on-demand-targeted-next-generation-sequencing-panels-for-inherited-disease-research-deliver-user-customization-without-high-upfront-cost-300461447.html


CHICAGO, May 24, 2017 (GLOBE NEWSWIRE) -- Dr. Andrea Califano, a pioneer in cancer systems biology and a renowned researcher at Columbia University, has joined the Tempus Scientific Advisory Board. In this role, he will serve as an advisor to the company and will bring his decades of experience researching the clinical implications of how DNA mutations and RNA expression levels interact at the proteomic level. A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/41e3b884-5da3-4ca3-be81-004d958c132b “I have spent my career working to determine the genetic drivers of cancer and believe that with the intersection of science and technology, we are on the verge of transforming the way cancer care is delivered,” said Dr. Andrea Califano. “I am excited to join the Scientific Board at Tempus and to help them accelerate the broad application of data in both the research and clinical environment.” Dr. Califano is the Clyde and Helen Wu Professor of Chemical Systems Biology at Columbia University Medical Center. He is the Founding Chair of the Department of Systems Biology, Director of the JP Sulzberger Columbia Genome Center, and Associate Director for Bioinformatics of the Herbert Irving Comprehensive Cancer Center, and also holds appointments in the Department of Biochemistry & Molecular Biophysics and Department of Biomedical Informatics. He joins the board along with Dr. Arul M. Chinnaiyan and Dr. David Agus. Meanwhile, DarwinHealth, a precision focused cancer medicine company, co-founded by Dr. Califano, that uses RNA analysis in an effort to match patients with treatments has partnered with Tempus on a personalized medicine research initiative aimed at improving outcomes for patients diagnosed with cancer. As part of the collaboration, Tempus will use information obtained from DarwinHealth reports in conjunction with approximately 2,000 de-identified patients for whom Tempus has done genetic sequencing of normal, tumor DNA and RNA in an effort to further explore protein interactions and tumor growth. The collaboration with DarwinHealth, using a systems biology approach to cancer care, will leverage the deep molecular and clinical data that Tempus collects daily, and the algorithms that Andrea has developed over the last decade, to help determine the driving force behind various cancers. “At Tempus, we are on a mission to recruit the best and brightest minds in cancer to help shape and guide the future of cancer treatment,” said Eric Lefkofsky, Co-founder and CEO at Tempus. “This partnership is consistent with that commitment as both Andrea and DarwinHealth are pioneering new ways to explore protein interactions that might open the door to an entirely new class of therapeutics.” Tempus provides molecular sequencing and clinical analytic solutions to top academic centers, hospital systems, associations, and healthcare providers. About Tempus: Tempus is a technology company that is building the world’s largest library of molecular and clinical data and an operating system to make that data accessible and useful. We enable physicians to deliver personalized cancer care for patients through our interactive analytical and machine learning platform. We provide genomic sequencing services and analyze molecular and therapeutic data to empower physicians to make real-time, data-driven decisions. Our goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as we gather more data. For more information, visit tempus.com.


Dublin, May 25, 2017 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Biophotonics - A Global Market Overview" report to their offering. The market for Biophotonics forecast to be US$36.8 billion in 2017 and projected to reach US$59.9 billion by 2022 at a CAGR of robust 10.2% between 2017 and 2022. Imaging estimated the largest consumer of biophotonics with market worth US$20.3 billion 2017 and projected to grow by a CAGR of 10.3% during the same analysis period. Analytics & Sensing applications anticipated to grow at a faster phase at a CAGR of 10.4% to reach US$19.4 billion by 2022. The study exclusively analyzes the Biophotonics applications/sub-types, technologies and application sectors are analyzed in terms of USD for 2014-2022 analysis period across the global markets comprising North America, Europe, Asia-Pacific, Latin America and Rest of World. Global market for Biophotonics applications analyzed in this study include Analytics & Sensing, Imaging, and Processing & Curing. These applications further categorized in to Analytics & Sensing - Biosensors, Molecular Spectroscopy, Other Analytics & Sensing Applications; Imaging - Inside Imaging (Endoscopy), Optical Microscopy, See-Through Imaging and Surface Imaging; and Processing & Curing - Light Therapy and Other Processing & Curing. The report also explores the global markets of Biophotonics by end-use sectors comprising Medical Diagnostics, Medical Therapeutics, Tests & Components and Non-Medical Applications while special focus on technologies including In Vitro and In Vivo. Advancements in optical technology, high incidences of chronic diseases and increasing demand for minimally invasive surgeries are also contributing to the growth in Biophotonics. Emerging economies have yet to fully exploit the opportunities offered by Biophotonics, which is slated to propel demand in regions such as Asia-Pacific and Latin America. Despite these developments, it is anticipated that a bulk of the market for Biophotonics would be accounted for by its use in the medical sector. The technology offers capability of addressing some of the essential healthcare needs of an aging global population, which will remain a key factor in bolstering demand. Other significant factors contributing to growth in the market for Biophotonics include ongoing research and development activities in various applications and government support for novel cost-effective medical technologies. Key Topics Covered: 1. Introduction 1.1 Product Outline 1.1.1 A Primer on Photonics 1.1.2 An Overview of Biophotonics 2. Applications and End-Use Sectors 2.1 Biophotonics Applications 2.1.1 Analytics & Sensing 2.1.2 Imaging 2.1.3 Processing & Curing 2.2 End-Use Sectors For Biophotonics 2.2.1 Medical Diagnostics 2.2.2 Medical Therapeutics 3. Key Market Trends 3.1 Concurrent Imaging of 24 Molecules Enabled by Innovative Microscopy Platform 3.2 Innovative "Smart Needle" Makes Brain Surgery Safer 3.3 Medically Monitoring Cameras Show Promise as Alternatives to Skin Sensors 3.4 Disease Detection Made Easier with Nanoscale Sensor 3.5 Detection of Next-Generation DNA Sequencing Reactions Enabled with Smartphone Microscope 3.6 Monitoring of Brain's Response to Pain Facilitated with Optical Tool 3.7 Retinal Camera Eliminates the Need for Dilating Pupils 3.8 Biophotonics Expands Traditional Realms of Radiology 3.9 Rapid and Accurate Detection of Bacterial Growth in Perishables Enabled with TDLAS 3.10 Novel Biophotonic Light Sensor for Detecting Legionella Bacteria 3.11 Nanostructure-Based Biophotonics Enables Wide-Ranging Detection 3.12 Innovative Optical Technology for Effective Monitoring of Blood Glucose Levels on the Cards 3.13 Identification of Unstable Plaques Made Possible with Biophotonics 3.14 Revolutionary Raman Imaging Technique Promises Improved Cancer Detection 4. Key Global Players - Becton, Dickinson and Company (United States) - Biolase, Inc. (United States) - Bio-Rad Laboratories, Inc. (United States) - Biotek Instruments, Inc. (United States) - Carl Zeiss AG (Germany) - Coherent Inc. (United States) - Hamamatsu Photonics K.K. (Japan) - Horiba, Ltd. (Japan) - II-VI Incorporated (United States) - Lumenis Ltd. (Israel) - Newport Corporation (United States) - Olympus Corporation (Japan) - Olympus Corporation of the Americas (United States) - Perkinelmer Inc. (United States) - Picoquant (Germany) - Thermo Fisher Scientific Inc. (United States) - FEI Company, Inc. (United States) - Toshiba Medical Systems Corporation (Japan) - Zecotek Photonics Inc. (Canada) 5. Key Business Trends - Horiba Scientific and Manta Instruments, Inc Enter into Distribution Agreement - PicoQuant Launches Two new Single Photon Sensitive Hybrid Photo Detector - Oxford Instruments Asylum Research Unveils new SurfRider HQ-Series AFM Probes - Beckman Receives FDA Clearance for its DxC 700 AU Chemistry Analyzer - Beckman Unveils CytoFLEX LX flow Cytometer - BioTek Expands in China - ZEISS Unveils ZEISS EXTARO 300 Visual System - ZEISS Introduces ZEISS Crossbeam 550 Image System - Hitachi Technologies Develops new Transmission Electron Microscope (TEM)*1 model, the HT7800 Series - Thermo Fisher Introduces new robust iN5 FTIR microscope - Andor Unveils new iXon Life Camera Platform for Fluorescence Microscopy - Oxford Instruments Asylum Research Releases New Cypher VRS Video-Rate Atomic Force Microscope - Becton Announces Early Access Program for BD Resolve Single-Cell Analysis Platform - 510(k) FDA clearance and Worldwide Launch for BIOLASE's Waterlase Express All-Tissue Laser System - Bruker Launches MALDI PharmaPulse 2.0 Screening Solution - FUJIFILM Europe Releases ELUXEO Endoscopy System - GE Healthcare and Boston Children's Hospital Join Forces to Develop Imaging Technology - Andor Launches Ultrafast Spectroscopy-enabled sCMOS Detectors - FDA Clearance and Worldwide Launch of new Epic Pro Diode Laser System from BIOLASE - Bio-Rad to Acquire RainDance Tech - PerkinElmer, Inc Unveils Vectra® Polaris Automated Quantitative Pathology Imaging System - Bitplane Launches Imaris 8.4 Filament Tracer - Leica Microsystems Enters into Agreement with Columbia University - Olympus Corporation Launches New Olympus DP74 Color Microscope Camera - Becton Unveils diagnostic instrument BD Phoenix M50 ID/AST - BIOLASE Inks a Clinical Research Agreement with McGuire Institute - Bruker to Acquire Preclinical PET Imaging Business of Oncovision - ENDRA Launches Nexus 128+ photoacoustic Imaging Solution - Shimadzu Corporation Releases SPM-9700HT Scanning Probe Microscope - Ocean Optics Releases New SERS Nanosponge Substrate for Raman Spectroscopy Applications - Andor Introduces Dragonfly, a new Imaging Solution - Bruker Releases In-Vivo Xtreme II Optical Preclinical Imaging System - Oxford Instruments Plc Introduces X-MET8000 series of X-ray fluorescence (XRF) analyzers - Bruker Releases Scanning Microwave Impedance Microscopy Solution - Bruker Unveils S4 TStar, a Total Reflection X-ray Fluorescence (TXRF) Spectrometer - ENDRA and GE Healthcare Collaborate - Thermo Fisher Acquires FEI Company - Olympus Medical Introduces EZ Shot 3 Plus single use Aspiration Needle for Endoscopic Application - BioTek and MilliporeSigma Collaborate - MedCom GmbH and Hitachi Medical Systems Europe Enter into Distribution Agreement - Becton Launches a novel cell analyzer BD FACSymphony system - Bio-Rad Announces CE IVD marking for its QX200 Droplet Digital PCR (ddPCR) System - Biophotonic Unveils new Pulse Shaping System, FemtoJockD - Boston Launches LithoVue Single-Use Digital Flexible Ureteroscope - Nikon Corporation Introduces new Inverted Routine Microscope ECLIPSE Ts2 - Andor Launches new Ultrasensitive Zyla 4.2 PLUS Scientific CMOS (sCMOS) Camera - Bruker Launches new SKYSCAN 1275 Automated, Desktop Micro-CT System - Boston Completes the Acquisition of American Medical Systems' (AMS) Men's Health and Prostate Health business - OpGen, Inc. Plans to Acquire AdvanDx, Inc. - OpGen, Inc Launches Next-Generation Molecular Testing and Bioinformatics for Combating Multi-Drug Resistant Infections - Bio-Rad Introduces BioPlex® 2200 25-OH Vitamin D kit - Leica Microsystems Unveils Inverted Microscope, Leica DMi8 - Boston Introduces Next Generation SpyGlass DS Direct Visualization System - Beckman to Acquire Clinical Microbiology Business from Siemens Healthcare Diagnostics - Boston Unveils new POLARIS Imaging System - Beckman Releases new Aquios CL Clinical Flow Cytometer 6. Global Market Overview For more information about this report visit http://www.researchandmarkets.com/research/3vgm3p/biophotonics_a


CHICAGO, May 24, 2017 (GLOBE NEWSWIRE) -- Dr. Andrea Califano, a pioneer in cancer systems biology and a renowned researcher at Columbia University, has joined the Tempus Scientific Advisory Board. In this role, he will serve as an advisor to the company and will bring his decades of experience researching the clinical implications of how DNA mutations and RNA expression levels interact at the proteomic level. A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/41e3b884-5da3-4ca3-be81-004d958c132b “I have spent my career working to determine the genetic drivers of cancer and believe that with the intersection of science and technology, we are on the verge of transforming the way cancer care is delivered,” said Dr. Andrea Califano. “I am excited to join the Scientific Board at Tempus and to help them accelerate the broad application of data in both the research and clinical environment.” Dr. Califano is the Clyde and Helen Wu Professor of Chemical Systems Biology at Columbia University Medical Center. He is the Founding Chair of the Department of Systems Biology, Director of the JP Sulzberger Columbia Genome Center, and Associate Director for Bioinformatics of the Herbert Irving Comprehensive Cancer Center, and also holds appointments in the Department of Biochemistry & Molecular Biophysics and Department of Biomedical Informatics. He joins the board along with Dr. Arul M. Chinnaiyan and Dr. David Agus. Meanwhile, DarwinHealth, a precision focused cancer medicine company, co-founded by Dr. Califano, that uses RNA analysis in an effort to match patients with treatments has partnered with Tempus on a personalized medicine research initiative aimed at improving outcomes for patients diagnosed with cancer. As part of the collaboration, Tempus will use information obtained from DarwinHealth reports in conjunction with approximately 2,000 de-identified patients for whom Tempus has done genetic sequencing of normal, tumor DNA and RNA in an effort to further explore protein interactions and tumor growth. The collaboration with DarwinHealth, using a systems biology approach to cancer care, will leverage the deep molecular and clinical data that Tempus collects daily, and the algorithms that Andrea has developed over the last decade, to help determine the driving force behind various cancers. “At Tempus, we are on a mission to recruit the best and brightest minds in cancer to help shape and guide the future of cancer treatment,” said Eric Lefkofsky, Co-founder and CEO at Tempus. “This partnership is consistent with that commitment as both Andrea and DarwinHealth are pioneering new ways to explore protein interactions that might open the door to an entirely new class of therapeutics.” Tempus provides molecular sequencing and clinical analytic solutions to top academic centers, hospital systems, associations, and healthcare providers. About Tempus: Tempus is a technology company that is building the world’s largest library of molecular and clinical data and an operating system to make that data accessible and useful. We enable physicians to deliver personalized cancer care for patients through our interactive analytical and machine learning platform. We provide genomic sequencing services and analyze molecular and therapeutic data to empower physicians to make real-time, data-driven decisions. Our goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as we gather more data. For more information, visit tempus.com.

Loading Bioinformatics collaborators
Loading Bioinformatics collaborators